MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

Sponsor: Pfizer

Sponsor score: 60
Inactive

ClinicalTrials ID:NCT04649359

Patient View

The MagnetisMM-3 trial evaluates Elranatamab, a BCMA-CD3 bispecific antibody, in relapsed/refractory multiple myeloma patients. Eligible participants must have measurable disease, be refractory to at least one IMiD, PI, and anti-CD38 mAb, and have an ECOG status ≤2. The study includes two cohorts based on prior BCMA-directed therapy exposure. Participants must not be pregnant and agree to use contraception.

Patient Parameters

Program Overview

The purpose of the study is to evaluate whether single-agent Elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of Elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of multiple myeloma (IMWG criteria, Rajkumar et al, 2014)

  • Measurable disease, as defined by at least 1 of the following:

    1. Serum M-protein >0.5 g/dL by SPEP
    2. Urinary M-protein excretion >200 mg/24 hours by UPEP
    3. Serum immunoglobulin FLC≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio

  • Refractory to at least one IMiD

  • Refractory to at least one PI

  • Refractory to at least one anti-CD38 antibody

  • Relapsed/refractory to last anti-myeloma regimen

  • Cohort A: has not received prior BCMA-directed therapy

  • Cohort B: has received prior BCMA-directed therapy (ADC or CAR T cells)

  • ECOG performance status ≤2

  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade ≤1

  • Not pregnant and willing to use contraception

Exclusion Criteria

  • Smoldering multiple myeloma
  • Active Plasma cell leukemia
  • Amyloidosis
  • POEMS syndrome
  • Stem cell transplant within 12 weeks prior to enrollment
  • Active HBV, HCV, SARS-CoV2, HIV, or any active, uncontrolled bacterial, fungal, or viral infection
  • Any other active malignancy within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ.
  • Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer)

Get This Program In Your Inbox

You can sign up and apply your patients for this program.